Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
NEW YORK (Reuters Health) – New research does not support the routine use of hematopoietic stem cell transplantation (HSCT) in infants with acute lymphoblastic leukemia (ALL) with mixed…
NEW YORK (Reuters Health) – Over time, cervical intraepithelial neoplasia (CIN) grade 2 eventually resolves spontaneously in about two-thirds of adolescent and young adult women, according to findings…
NEW YORK (Reuters Health) – The tumor volume threshold of 0.5 mL for clinically insignificant prostate cancer, established in the early 1990s, remains valid, according to researchers who…
NEW YORK (Reuters Health) – There appear to be several problems with the current clinical staging criteria for localized prostate cancer, according to a study published online today…
NEW YORK (Reuters Health) – Outcomes of cryoablation of small renal masses are similar whether the procedure is performed surgically or percutaneously, according the results of a meta-analysis…
NEW YORK (Reuters Health) – The likelihood that a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive breast cancer on final…
NEW YORK (Reuters Health) – In terms of overall survival, carboplatin plus the oral fluoropyrimidine derivative S-1 is as effective as carboplatin plus paclitaxel in chemotherapy-naive patients with…
NEW YORK (Reuters Health) – Patients with papillary thyroid cancer who undergo lobectomy do as well as those who undergo total thyroidectomy, while external beam radiation is associated…
NEW YORK (Reuters Health) – The risk of second primary neoplasms (SPNs) of the central nervous system in survivors of childhood cancer increases greatly with the dose of…
NEW YORK (Reuters Health) – The off-label use of recombinant factor VIIa for hemostasis in patients without hemophilia confers only modest benefits but may increase the risk of…
